Fernanda Andrade Orsi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6180362/publications.pdf

Version: 2024-02-01

471509 610901 106 874 17 24 h-index g-index citations papers 119 119 119 1397 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahidrofolate reductase among patients with sickle cell disease in Brazil., 1998, 59, 46-50.		57
2	Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets, 2008, 19, 489-495.	2.3	46
3	Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transplant Infectious Disease, 2003, 5, 167-173.	1.7	40
4	Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias. Scientific Reports, 2017, 7, 3355.	3.3	35
5	Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case–control study comparing dengue fever patients with and without bleeding manifestations. BMC Infectious Diseases, 2013, 13, 350.	2.9	30
6	Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thrombosis Research, 2015, 136, 1174-1178.	1.7	28
7	Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy. Hematology, Transfusion and Cell Therapy, 2020, 42, 300-308.	0.2	28
8	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 297-303.	3.8	27
9	Impaired Thrombin Generation in Patients with Dengue Blood, 2012, 120, 2240-2240.	1.4	27
10	Increased ADAMTS13 activity in patients with venous thromboembolism. Thrombosis Research, 2012, 130, 889-893.	1.7	26
11	Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Journal of Thrombosis and Haemostasis, 2019, 17, 319-328.	3.8	25
12	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093635.	1.7	25
13	Increased adhesive properties of neutrophils and inflammatory markers in venous thromboembolism patients with residual vein occlusion and high D-dimer levels. Thrombosis Research, 2014, 133, 736-742.	1.7	24
14	Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis. Thrombosis Research, 2015, 135, 497-501.	1.7	24
15	Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. Platelets, 2009, 20, 367-375.	2.3	23
16	Safety and efficacy of cryoprecipitateâ€poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: A single center retrospective evaluation. Journal of Clinical Apheresis, 2014, 29, 311-315.	1.3	22
17	Polymorphisms and Mutations in <i>vWF</i> and <i>ADAMTS13</i> Genes and Their Correlation With Plasma Levels of FVIII and vWF in Patients With Deep Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 514-518.	1.7	19
18	Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. Vascular Pharmacology, 2020, 124, 106608.	2.1	19

#	Article	IF	CITATIONS
19	Glucocorticoid use and risk of first and recurrent venous thromboembolism: selfâ€controlled caseâ€series and cohort study. British Journal of Haematology, 2021, 193, 1194-1202.	2.5	19
20	Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome. PLoS ONE, 2020, 15, e0227150.	2.5	18
21	Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus. PLoS ONE, 2015, 10, e0132784.	2.5	17
22	A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection. Transfusion, 2010, 50, 208-212.	1.6	16
23	<p>Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk</p> . Clinical Epidemiology, 2019, Volume 11, 625-633.	3.0	16
24	CD144, CD146 and VEGFR-2 properly identify circulating endothelial cell. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 98-102.	0.7	15
25	VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thrombosis Research, 2010, 126, e206-e210.	1.7	14
26	Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2019, 45, 825-833.	2.7	13
27	Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. Thrombosis Research, 2022, 214, 132-137.	1.7	13
28	Changes in AgNOR configurations during the evolution and treatment of chronic lymphocytic leukemia. Hematology and Cell Therapy, 1999, 41, 205-210.	0.7	11
29	Prevalence of Factor IX-R338L (Factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels. Thrombosis Research, 2010, 126, e165.	1.7	11
30	Laboratory evaluation of patients with undiagnosed bleeding disorders. Blood Coagulation and Fibrinolysis, 2016, 27, 500-505.	1.0	11
31	The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. American Journal of Hematology, 2017, 92, 1163-1169.	4.1	11
32	Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagulation and Fibrinolysis, 2012, 23, 75-77.	1.0	10
33	Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome. Thrombosis Research, 2018, 171, 114-120.	1.7	10
34	Risk Factors for Transfusion after Orthotopic Liver Transplantation. Transfusion Medicine and Hemotherapy, 2019, 46, 431-439.	1.6	10
35	Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome. Journal of Thrombosis and Thrombolysis, 2020, 50, 772-781.	2.1	9
36	Long-term prospective study of recurrent venous thromboembolism in a Hispanic population. Blood Coagulation and Fibrinolysis, 2010, 21, 660-665.	1.0	8

#	Article	IF	Citations
37	A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response. Journal of Thrombosis and Haemostasis, 2021, 19, 2275-2286.	3.8	8
38	Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR. Journal of Thrombosis and Thrombolysis, 2016, 42, 146-153.	2.1	6
39	Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event. Journal of Thrombosis and Thrombolysis, 2022, 53, 30-42.	2.1	6
40	Performance of a point-of-care device in determining prothrombin time in an anticoagulation clinic. Blood Coagulation and Fibrinolysis, 2012, 23, 172-174.	1.0	5
41	Clinical implications of the detection of antibodies directed against domain 1 of $\hat{1}^2$ 2-glycoprotein 1 in thrombotic antiphospholipid syndrome. Thrombosis Research, 2016, 148, 32-37.	1.7	5
42	Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome. Journal of Thrombosis and Thrombolysis, 2021, 52, 730-737.	2.1	5
43	Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: A case report. Platelets, 2015, 26, 263-266.	2.3	4
44	Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 477-482.	1.7	4
45	Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies. European Journal of Internal Medicine, 2019, 69, e6-e7.	2.2	4
46	Evaluation of ADAMTS13 Activity and Inflammatory Markers in Deep Venous Thrombosis Patients. Blood, 2011, 118, 5246-5246.	1.4	4
47	Circulating Levels of Ang/Tie2 and VEGF-a Pathway Mediators Are Associated with Clinical Severity, Endothelial Barrier Disruption and Coagulation Activation in COVID-19. Blood, 2021, 138, 2073-2073.	1.4	4
48	Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome. Lupus, 2022, 31, 1067-1077.	1.6	4
49	Bleeding complications in dengue are not associated with significant changes in the modulators of the endothelial barrier. Journal of Infection in Developing Countries, 2014, 8, 799-803.	1.2	3
50	Severe postthrombotic syndrome is associated with characteristic sonographic pattern of the residual thrombosis. Blood Coagulation and Fibrinolysis, 2016, 27, 673-678.	1.0	3
51	Self-perceived quality of life of primary antiphospholipid syndrome patients using vitamin K antagonist. Lupus, 2021, 30, 707-714.	1.6	3
52	Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome. European Journal of Internal Medicine, 2021, 90, 114-115.	2.2	3
53	Efficacy of a hypolipid diet in patients with primary antiphospholipid syndrome with dyslipidemia: a prospective study. Journal of Thrombosis and Thrombolysis, 2022, 53, 390-398.	2.1	3
54	Hydroxychloroquine Therapy and Netosis Regulators Expression in Patients with Primary Antiphospholipid Syndrome. Blood, 2018, 132, 5049-5049.	1.4	3

#	Article	IF	CITATIONS
55	Association of acidosis with coagulopathy and transfusion requirements in liver transplantation. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	3
56	Adenosine diphosphateâ€induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (tâ€PAPS): Role of P2Y12â€cAMP signaling pathway. Journal of Thrombosis and Haemostasis, 2022, 20, 1699-1711.	3.8	3
57	Performance of a pointâ€ofâ€care device in determining prothrombin time in supraâ€therapeutic <scp>INR</scp> s. International Journal of Laboratory Hematology, 2013, 35, 211-216.	1.3	2
58	Genetic variations in sites of affinity between FVIII and LRP1 are not associated with high FVIII levels in venous thromboembolism. Scientific Reports, 2015, 5, 9246.	3.3	2
59	Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model. PLoS ONE, 2019, 14, e0226871.	2.5	2
60	Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels. Blood, 2015, 126, 1049-1049.	1.4	2
61	Increased Levels of Endothelial Dysfunction Markers and Matrix Metalloproteinases in Patients with Severe Post-Thrombotic Syndrome. Blood, 2016, 128, 276-276.	1.4	2
62	Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2019, 134, 4894-4894.	1.4	2
63	Gene Variants Associated With Venous Thrombosis: A Replication Study in a Brazilian Multicentre Study. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962096222.	1.7	1
64	Expression of tissue factor mRNA in thrombosis associated with antiphospholipid syndrome. Journal of Thrombosis and Thrombolysis, 2021, 51, 370-378.	2.1	1
65	Misdiagnosis of high thrombotic risk triple-positive antiphospholipid antibodies. Thrombosis Research, 2021, 197, 33-35.	1.7	1
66	A Retrospective Analysis of 122 Immune Thrombocytopenia Patients Treated with Dapsone: Efficacy, Safety and Factors Associated with Treatment Response. Blood, 2018, 132, 737-737.	1.4	1
67	Study of the Role of Hydroxychloroquine in Immunomodulation and Control of Hypercoagulability in Patients Diagnosed with Primary Antiphospholipid Syndrome. Blood, 2019, 134, 3682-3682.	1.4	1
68	ADAMTS13 ACTIVITY and VON Willebrand FACTOR LEVELS IN PATIENTS with Livedoid VASCULOPATHY Blood, 2009, 114, 5064-5064.	1.4	1
69	Increased Expression of Secretory Leukocyte Protease Inhibitor (SLPI) In Mononuclear Cells From Patients with Deep Vein Thrombosis. Blood, 2011, 118, 1232-1232.	1.4	1
70	Decreased Activity of ADAMTS13 In Patients with Deep Vein Thrombosis Associated with Inflammatory Markers. Blood, 2010, 116, 3181-3181.	1.4	1
71	Increased Neutrophil Adhesive Properties In Patients with Venous Thromboembolism and Residual Vein Thrombosis and High D-Dimer Levels. Blood, 2011, 118, 2301-2301.	1.4	1
72	Plasma Factor VIII Levels as a Biomarker for Venous Thromboembolism., 2015, , 1-19.		1

#	Article	lF	Citations
73	HIPERCOAGULABILIDADE, EVENTOS TROMBOEMBÓLICOS E ANTICOAGULAÇÃO NA COVID-19. Revista Da Sociedade De Cardiologia Do Estado De São Paulo, 2020, 30, 462-471.	0.2	1
74	Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies: Author´s reply. European Journal of Internal Medicine, 2020, 74, 108-109.	2.2	O
75	Obstetric antiphospholipid syndrome. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 495-501.	0.8	O
76	Janus Kinase (JAK2) V617F Somatic Mutation in Patients with Deep Vein Thrombosis Blood, 2007, 110, 1645-1645.	1.4	O
77	DECREASED ACTIVITY of ADAMTS13 IN PATIENTS with DEEP Vein Thrombosis Blood, 2009, 114, 3991-3991.	1.4	O
78	VKORC1 V66M Mutation in African Brazilian Patient Resistant to Oral Anticoagulant Therapy Blood, 2009, 114, 2102-2102.	1.4	O
79	Prevalence of FACTOR IX-R338L (FACTOR IX PADUA) IN A COHORT of PATIENTS with Venous Thromboembolism and Mild Elevation of FACTOR IX LEVELS Blood, 2009, 114, 5057-5057.	1.4	O
80	Analysis of the Genetic Expression of Inflammatory Mediators From Patients with Spontaneous Deep Venous Thrombosis. Blood, 2011, 118, 5251-5251.	1.4	O
81	Metabolic and Inflamatory Proteins Differently Expressed in Platelets From Deep Venous Thrombosis Patients. Blood, 2011, 118, 5256-5256.	1.4	O
82	Prospective Evaluation of plasma Levels of FVIII in Patients with venous Thromboembolism,. Blood, 2011, 118, 3348-3348.	1.4	O
83	Endothelial Activation, FVW and ADAMTS 13 imbalance and Fibrinolysis Impairment in Adults with Dengue Fever with Bleeding Complications,. Blood, 2011, 118, 3325-3325.	1.4	O
84	Thrombotic Thrombocytopenic Purpura Triggered by Inflammatory Pseudotumor: A Report of a Rare Case. Blood, 2012, 120, 4660-4660.	1.4	O
85	Metabolic and Inflammatory Proteins Differentially Expressed in Platelets from Unprovoked Deep Vein Thrombosis Patients. Journal of Proteomics and Bioinformatics, 2014, 07, .	0.4	O
86	Circulating Endothelial Cells Are Increased in Post-Thrombotic Syndrome Patients. Blood, 2014, 124, 4997-4997.	1.4	O
87	Lower Echogenicity of the Residual Venous Thrombosis at Ultrasound Examination Is Associated to Recurrent Thrombosis Events. Blood, 2014, 124, 4251-4251.	1.4	O
88	Severe Post Thrombotic Syndrome Is Associated to Lower Echogenicity of the Residual Venous Thrombosis. Blood, 2014, 124, 4252-4252.	1.4	0
89	Inhibition of Sorbitol Dehydrogenase Increases Platelets Adhesion in Animals Mice with Fidarestat. Blood, 2014, 124, 5081-5081.	1.4	O
90	Adhesive Properties of Neutrophils as a Possible Biomarker of Vascular Disease., 2015, , 1-19.		0

#	Article	IF	CITATIONS
91	Signs of Hypofibrinolysis in Patients with Unprovoked Idiopathic Venous Thromboembolism. Blood, 2015, 126, 3556-3556.	1.4	O
92	Increased D-Dimer Levels and Residual Venous Thrombosis Are Associated with Late Recurrence of Deep Venous Thrombosis. Blood, 2015, 126, 3554-3554.	1.4	0
93	Antibodies Directed Against the Domain 1 of Beta2-Glicoprotein 1 May be Associated with Secondary Antiphospholipid Syndrome. Blood, 2015, 126, 768-768.	1.4	O
94	Adhesive Properties of Neutrophils as a Possible Biomarker of Vascular Disease., 2016,, 985-1003.		0
95	Plasma Factor VIII Levels as a Biomarker for Venous Thromboembolism. , 2016, , 703-721.		O
96	Procoagulant Profile in Primary Antiphospholipid Syndrome Is Not Dependent upon Increased Inflammatory Response. Blood, 2016, 128, 3817-3817.	1.4	0
97	Increased Inflammatory Properties of Neutrophils in Patients with Venous Thromboembolism and the Effect of Simvastatin on Abrogating Inflamed Neutrophils Adhesiveness. Blood, 2016, 128, 3681-3681.	1.4	O
98	Association of Risk of Incident and Recurrent Venous Thromboembolism with Oral Glucocorticoid Treatment. Blood, 2018, 132, 420-420.	1.4	0
99	Clinical Course of Primary Immune Thrombocytopenia with Positive Antiphospholipid Antibodies. Blood, 2018, 132, 1159-1159.	1.4	O
100	Drug Repurposing for the Treatment of Severe COVID-19 and the Impact on Disease Outcomes. SSRN Electronic Journal, $0,$	0.4	0
101	COVID-19 Diagnosis and Its Impact on Thrombotic Risk in a Cohort of Patients Simultaneously Hospitalized Due to Acute Respiratory Distress Syndrome. Blood, 2021, 138, 780-780.	1.4	O
102	Answer to "REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome― Journal of Thrombosis and Thrombolysis, 2022, , .	2.1	0
103	Title is missing!. , 2019, 14, e0226871.		O
104	Title is missing!. , 2019, 14, e0226871.		0
105	Title is missing!. , 2019, 14, e0226871.		0
106	Title is missing!. , 2019, 14, e0226871.		0